Calcium channel antagonists. Part IV: Side effects and contraindications drug interactions and combinations
The DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.
Abstract
With the correct selection of drug and patient, the calcium antagonists as a group can be remarkably effective at relatively low cost of serious side effects. Almost all side effects are dose related. Minor side effects include those caused by vasodilation (flushing and headaches), constipation (verapamil), and ankle edema. Serious side effects are rare and result from improper use of these agents, as when intravenous verapamil (or diltiazem) is given to patients with sinus or atrioventricular nodal depression from drugs or disease, or nifedipine to patients with aortic stenosis. The potential of a marked negative inotropic effect is usually offset by afterload reduction, especially in the case of nifedipine which actually has the most marked negative inotropic effect. Yet caution is required when even calcium antagonists, especially verapamil, are given to patients with myocardial failure unless caused by hypertensive heart disease. Drug interactions of calcium antagonists occur with other cardiovascular agents such as alpha-adrenergic blockers, beta-adrenergic blockers, digoxin, quinidine, and disopyramide. The most marked interaction with digoxin is that with verapamil, which may raise digoxin levels by over 50%. Combination therapy of calcium antagonists with beta-blockers is increasingly common, and is probably safest in the case of dihydropyridines. Other combinations being explored are those with angiotensin-converting enzyme inhibitors and diuretics.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, some pharmacological side effects may be more effectively managed with exercise interventions rather than adding further medications to the patient’s regimen, potentially initiating a harmful “prescription cascade” [[544], [545], [546], [547]].”
From Global consensus on optimal exercise recommendations for enhancing healthy longevity in older adults (ICFSR) (2025) · cites this paper as [544]
Citations
Cites
Diltiazem: A Review of its Pharmacological Properties and Therapeutic Efficacy
Chaffman, M., & Brogden, R. N. (1985) · Drugs · doi:10.2165/00003495-198529050-00001 · Cited by 373 · cited 1×
“Besides additive effects on nodal tissue and additive negative inotropic effects, diltiazem can displace propranolol from plasma binding sites thereby elevating free propranolol levels [ 69 ].”
BackgroundSorkin, E. M., Clissold, S. P., & Brogden, R. N. (1985) · Drugs · doi:10.2165/00003495-198530030-00002 · Cited by 355 · cited 1×
“Nifedipine data from [3], [15], [16], [99], and [100]. See also [ 101 ].”
BackgroundTorsade De Pointes, an atypical ventricular tachycardia.
Krikler, D. M., & Curry, P. V. (1976) · Heart · doi:10.1136/hrt.38.2.117 · Cited by 344 · cited 1×
“Such side effects have not been reported with the three prototypical calcium antagonists but only with prenylamine, lidoflazine, and bepridil which may all prolong the Q-T interval with potential for precipitation of atypical ventricular tachycardia [45].”
BackgroundHemodynamic consequences of combined beta-adrenergic and slow calcium channel blockade in man.
Packer, M., Meller, J., Medina, N., Yushak, M., Smith, H., Holt, J., Guererro, J., Todd, G. D., McAllister, R. G., & Gorlin, R. (1982) · Circulation · doi:10.1161/01.cir.65.4.660 · Cited by 332 · cited 1×
“verapamil [56] can reduce contractility [56], increase”
Calcium Antagonists and Cardiovascular Disease
McGoon, M. D. (1985) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)60308-5 · Cited by 232
Nifedipine in hypertensive emergencies.
Bertel, O., Conen, D., Radü, E. W., Müller, J., Lang, C., & Dubach, U. C. (1983) · BMJ · doi:10.1136/bmj.286.6358.19 · Cited by 222
Roth, A., Harrison, E., Mitani, G., Cohen, J., Rahimtoola, S. H., & Elkayam, U. (1986) · Circulation · doi:10.1161/01.cir.73.2.316 · Cited by 196 · cited 2×
“Diltiazem 360 mg daily given instead of digoxin caused side effects in 9 of 12 patients (75%) with atrial fibrillation; 11 of these patients had mitral valve disease [38].”
BackgroundLynch, P., Dargie, H., Krikler, S., & Krikler, D. (1980) · BMJ · doi:10.1136/bmj.281.6234.184 · Cited by 191
Treatment of variant angina with drugs: a survey of 11 cardiology institutes in Japan.
Kimura, E., & Kishida, H. (1981) · Circulation · doi:10.1161/01.cir.63.4.844 · Cited by 190 · cited 1×
“In a small open series [74], nifedipine plus diltiazem appears to be effective in all”
BackgroundDifferential cardiovascular effects of calcium channel blocking agents: Potential mechanisms
Millard, R. W., Lathrop, D. A., Grupp, G., Ashraf, M., Grupp, I. L., & Schwartz, A. (1982) · The American Journal of Cardiology · doi:10.1016/s0002-9149(82)80002-7 · Cited by 187 · cited 1×
“dipine may be considerably more powerful than verapamil or diltiazem in decreasing vagal tone [61],”
Background
Research works printed but not linked: 11
- Fleckenstein A. Specific inhibitors and promoters of calcium action in the excitation-contraction coupling of heart muscle and their role in the prevention or production of myocardial lesions. In: Harris P, Opie LH, eds. Calcium and the Heart. London: Academic Press, 1971;135?188.
- Opie LH, Singh BN. Calcium channel antagonists (slow channel blockers). In: Opie LH, ed. Drugs for the Heart Second Expanded Edition. Orlando, Florida: Grune & Stratton, 1987;34?53
- Norris RJ, Brooks SG. Pharmacokinetics of a sustained release formulation of verapamil in young and elderly adults. In: Raftery EB, ed. Verapamil SR. Once-daily Calcium Blockade in Angina and Hypertension. Langhorne: ADIS Press International, 1987;38?46.
- Leisten L, Kuhlmann J, Ebner F. Side effects and pharmacodynamic interactions. In: Krebs R, ed. Treatment of Cardiovascular Diseases by Adalat R (Nifedipine). Stuttgart-New York: Schattauer, 1986;270?314.
- Jee LD, Opie LH. Nifedipine for hypertension and angina pectoris: Interactions during combination therapy. In: Opie LH, ed. Calcium Antagonists and Cardiovascular Disease. New York: Raven Press, 1984;339?346.
- Bardet J, Baudet M, Rigaud M, et al. Diltiazem, a new calcium antagonist, versus propranolol in treatment of spontaneous angina pectoris (abstr). Am J Cardiol 1979; 43:416.
- Menasche S, Elkik F, Cocco G, et al. Synergistic antihypertensive effect of diltiazem combined with the alpha-adrenoceptor blocker alfuzosine (abstr). Ann NY Acad Sci (in press).
- Kleinbloesem CH, van Brummelen P, Sandberg THW, et al. Kinetic and haemodynamic interactions between nifedipine and propranolol in healthy subjects utilizing controlled rates of drug input. In: Kleinbloesem CH, ed. Nifedipine: Clinical Pharmacokinetics and Haemodynamic Effects. 's-Gravenhage: Drukkerij JH Pasmans BV, 1985;151?165.
- Kirch W. Dihydropyridine derivatives, influence on digoxin disposition and haemodynamics (abstr). Ann NY Acad Sci (in press).
- MacGregor GA: Hypertension. In: Krebs R, ed. Treatment of Cardiovascular Diseases by Adalat R (Nifedipine). Stuttgart: Schattauer, 1986; 231?258.
- Lahiri A, Dasgupta P, Rodrigues EA, et al. Acute drug withdrawal in patients with stable angina on long-term treatment with verapamil. In: Raftery EB, ed. Verapamil SR. Langhorne: ADIS Press International, 1987;18?29.
Cited by
Izquierdo, M., de Souto Barreto, P., Arai, H., Bischoff-Ferrari, H. A., Cadore, E. L., Cesari, M., Chen, L.-K., Coen, P. M., Courneya, K. S., Duque, G., et al. (2025) · The Journal of nutrition, health and aging · doi:10.1016/j.jnha.2024.100401 · Cited by 273
Cipriani, A., Saunders, K., Attenburrow, M.-J., Stefaniak, J., Panchal, P., Stockton, S., Lane, T. A., Tunbridge, E. M., Geddes, J. R., & Harrison, P. J. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.86 · Cited by 111
Ro 40–5967: A New Nondihydropyridine Calcium Antagonist
Clozel, J., Osterrieder, W., Kleinbloesem, C. H., Welker, H. A., Schläppi, B., Tudor, R., Hefti, F., Schmitt, R., & Eggers, H. (1991) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.1991.tb00539.x · Cited by 103
Calcium channel blockers, postural vasoconstriction and dependent oedema in essential hypertension
Pedrinelli, R., Dell’Omo, G., & Mariani, M. (2001) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001201 · Cited by 72
Stroke precipitated by moderate blood pressure reduction
Fischberg, G. M., Lozano, E., Rajamani, K., Ameriso, S., & Fisher, M. (2000) · Journal of Emergency Medicine · doi:10.1016/s0736-4679(00)00267-5 · Cited by 70
Metadata
- Authors
- Opie, L. H.
- Affiliations
- University of Cape Town (ZA)
- Corresponding author
- Opie, Lionel H.
- Venue
- Cardiovascular Drugs and Therapy
- Published
- 1988-07
- Volume
- 2
- Issue
- 2
- Pages
- 177-189
- ISSN
- 0920-3206 (ISSN-L)
- 1573-7241
- OpenAlex
- W1999013996
- Cited by
- 52
- References
- 99
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 1 · 2021: 5 · 2020: 2 · 2016: 1 · 2015: 1 · 2013: 1 · 2012: 1
- FWCI
- 1.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cardiovascular Drugs and Therapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion channel regulation and function
- Keywords
- calcium channel blockers, verapamil, diltiazem, nifedipine, adverse drug reactions, contraindications, drug interactions, beta-blocker combination therapy, dihydropyridines, negative inotropic effect, myocardial failure, aortic stenosis, alpha-blockers, ACE inhibitors, diuretics, vasodilation
- MeSH terms
- Calcium Channel Blockers, Cardiovascular Diseases, Drug Interactions, Drug Therapy, Combination, Humans
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.